Hims & Hers Health (NYSE:HIMS) Price Target Raised to $32.00

Key Points

• Bank of America raised its price target on Hims & Hers from $30 to $32 while maintaining a "neutral" rating, implying roughly a 13.6% upside from the current price.
• Quarterly results beat on EPS ($0.08 vs. $0.02 consensus) with revenue of $617.8M (up 28.4% YoY) but slightly below sales expectations.
• Mixed signals for investors: the consensus rating is "Hold" (average target $32.36) amid significant insider selling (~204,857 shares, ~$5.3M over three months), even as an expanded Eli Lilly partnership, menopause product launches and an FDA peptides review offer potential near‑term catalysts.

Hims & Hers Health (NYSE:HIMS - Get Free Report) had its target price hoisted by investment analysts at Bank of America from $30.00 to $32.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a "neutral" rating on the stock. Bank of America's target price would indicate a potential upside of 13.63% from the company's current price.

Several other brokerages have also recently commented on HIMS. Zacks Research upgraded shares of Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research report on Wednesday, February 25th. Evercore set a $24.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Truist Financial reaffirmed a "hold" rating and set a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a report on Tuesday, February 24th. Needham & Company LLC raised Hims & Hers Health from a "hold" rating to a "buy" rating and set a $30.00 price target on the stock in a research note on Monday, March 9th. Finally, Morgan Stanley decreased their price objective on Hims & Hers Health from $40.00 to $21.00 and set an "equal weight" rating for the company in a research note on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Hims & Hers Health currently has a consensus rating of "Hold" and an average target price of $32.36.

Hims & Hers Health Stock Down 2.9%

NYSE:HIMS opened at $28.16 on Friday. The stock's fifty day moving average price is $20.70 and its two-hundred day moving average price is $31.71. Hims & Hers Health has a 52-week low of $13.74 and a 52-week high of $70.43. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. The company has a market cap of $6.42 billion, a price-to-earnings ratio of 55.22, a P/E/G ratio of 2.75 and a beta of 2.32.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.02 by $0.06. The company had revenue of $617.82 million during the quarter, compared to analysts' expectations of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The business's revenue for the quarter was up 28.4% on a year-over-year basis. During the same period last year, the firm earned $0.11 EPS. On average, analysts anticipate that Hims & Hers Health will post 0.61 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Oluyemi Okupe sold 36,922 shares of the stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $25.90, for a total transaction of $956,279.80. Following the completion of the sale, the chief financial officer directly owned 281,867 shares of the company's stock, valued at approximately $7,300,355.30. This represents a 11.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 97,289 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the completion of the transaction, the chief operating officer directly owned 407,282 shares in the company, valued at approximately $10,055,792.58. The trade was a 19.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 204,857 shares of company stock valued at $5,285,706 in the last three months. Insiders own 13.71% of the company's stock.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently made changes to their positions in HIMS. Quent Capital LLC acquired a new stake in shares of Hims & Hers Health in the 3rd quarter valued at about $28,000. Flagship Harbor Advisors LLC bought a new position in shares of Hims & Hers Health during the fourth quarter worth about $28,000. Binnacle Investments Inc bought a new position in shares of Hims & Hers Health during the third quarter worth about $28,000. Bogart Wealth LLC raised its position in Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company's stock valued at $29,000 after buying an additional 632 shares during the last quarter. Finally, Geneos Wealth Management Inc. bought a new stake in Hims & Hers Health in the 1st quarter valued at approximately $30,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Expanded Eli Lilly tie‑up — HIMS said its platform can now connect patients to Eli Lilly self‑pay pricing and fulfill prescriptions for products like Zepbound (vials, KwikPen, Foundayo), a move that traders pushed as a near‑term revenue/traffic catalyst and drove a notable intraday rally. Hims & Hers stock surges 7% on Eli Lilly partnership expansion
• Positive Sentiment: Product expansion into menopause care — HIMS announced offering estrogen‑patch treatment options as U.S. demand rises, broadening its addressable market for recurring care and potentially boosting prescription revenue. Hims & Hers expands into menopause care
• Positive Sentiment: Regulatory/regenerative pipeline attention — An upcoming FDA Pharmacy Compounding Advisory Committee meeting on peptides has been viewed as a broader industry/regulatory tailwind that increases investor interest in HIMS’ peptide/adjacent opportunities. Hims stock price reacts strongly to crucial FDA review
• Neutral Sentiment: Media/sector flow amplifying moves — Broader appetite for telehealth/weight‑loss thematic names and coverage pieces (positive and critical) are amplifying volatility in HIMS independent of firm‑level results. News roundup: Hims shares rise on independent Rx fills
• Negative Sentiment: Insider selling — CFO Oluyemi Okupe and other insiders executed Rule 10b5‑1 sales (Okupe ~19,645 shares; Soleil Boughton also sold recently). While pre‑arranged plans limit signalling, the filings have weighed on sentiment and likely pressured near‑term trading. Oluyemi Okupe Sells 19,645 Shares
• Negative Sentiment: Execution and competition concerns — Coverage flagged doubts about HIMS’ newest obesity plan and heightened competition (e.g., Amazon’s weight‑loss program), which could compress margins or slow customer share gains if rollout/execution falter. Hims & Hers Reverses Amid Doubts About Its Newest Obesity Plan

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.